

Company Number: 629880

Zephyr Medical Affairs Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 July 2025

Zephyr Medical Affairs Limited
CONTENTS

| | Page |
|---------------------------------------|-------------|
| Director's Responsibilities Statement | 3 |
| Balance Sheet | 4 |
| Statement of Changes in Equity | 5 |
| Notes to the Financial Statements | 6 - 8 |

Zephyr Medical Affairs Limited

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 31 July 2025

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Caroline Kavanagh
Director

6 January 2026

Zephyr Medical Affairs Limited

BALANCE SHEET

as at 31 July 2025

| | Notes | 2025 € | 2024 € |
|---|-------|-----------|-----------|
| Fixed Assets | | | |
| Tangible assets | 5 | 1,252 | 1,789 |
| Current Assets | | | |
| Debtors | 6 | 24,612 | 21,600 |
| Cash and cash equivalents | | 2,669 | 5,939 |
| | | 27,281 | 27,539 |
| Creditors: amounts falling due within one year | 7 | (5,833) | (9,790) |
| Net Current Assets | | 21,448 | 17,749 |
| Total Assets less Current Liabilities | | 22,700 | 19,538 |
| Capital and Reserves | | | |
| Called up share capital presented as equity | | 100 | 100 |
| Retained earnings | | 22,600 | 19,438 |
| Equity attributable to owners of the company | | 22,700 | 19,538 |

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Zephyr Medical Affairs Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 6 January 2026 and signed on its behalf by:

Caroline Kavanagh
Director

Zephyr Medical Affairs Limited
STATEMENT OF CHANGES IN EQUITY
as at 31 July 2025

| | Called up share capital € | Retained earnings € | Total € |
|-------------------------------|--|------------------------------------|--------------------|
| At 1 August 2023 | 100 | 25,423 | 25,523 |
| Loss for the financial year | - | (5,985) | (5,985) |
| At 31 July 2024 | 100 | 19,438 | 19,538 |
| Profit for the financial year | - | 3,162 | 3,162 |
| At 31 July 2025 | 100 | 22,600 | 22,700 |

Zephyr Medical Affairs Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

1. General Information

Zephyr Medical Affairs Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 629880. The registered office of the company is 11 Chelsea Gardens, Clontarf, Dublin 3 which is also the principal place of business of the company. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 July 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

| | | |
|----------------------------------|---|-------------------|
| Fixtures, fittings and equipment | - | 20% Straight line |
|----------------------------------|---|-------------------|

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Employee benefits

The company operates a defined contribution pension scheme. Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Zephyr Medical Affairs Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

Financial Instruments

Cash and cash equivalents

Cash consists of cash on hand and demand deposits. Cash equivalents consist of short term highly liquid investments that are readily convertible to known amounts of cash that are subject to an insignificant risk of change in value.

Other financial assets and liabilities

Other financial assets including trade debtors arising from services provided to customers on short-term credit, are initially measured at the undiscounted amount of cash receivable from that debtor, which is normally the invoice price. If payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate, this constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, other financial assets are measured at amortised cost less impairment, where there is objective evidence of impairment.

Other financial liabilities, including trade creditors arising from goods purchased from suppliers on short-term credit, are initially measured at the undiscounted amount owed to the creditor, which is normally the invoice price. Liabilities that are settled within one year are not discounted. If payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate, this constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, other financial liabilities are measured at amortised cost.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

| | | |
|--|-------------------|-------------------|
| 3. Operating profit/(loss) | 2025 | 2024 |
| | € | € |
| Operating profit/(loss) is stated after charging: | | |
| Depreciation of tangible assets | 537 | 537 |
| | <u> </u> | <u> </u> |

4. Employees

The average monthly number of employees, including director, during the financial year was 1, (2024 - 1).

| | | |
|----------|-------------------|-------------------|
| | 2025 | 2024 |
| | Number | Number |
| Director | 1 | 1 |
| | <u> </u> | <u> </u> |

5. Tangible assets

| | | |
|-------------------------------|---|-------------------|
| | Fixtures, fittings and equipment | Total |
| | € | € |
| Cost | | |
| At 1 August 2024 | 2,683 | 2,683 |
| | <u> </u> | <u> </u> |
| At 31 July 2025 | 2,683 | 2,683 |
| | <u> </u> | <u> </u> |
| Depreciation | | |
| At 1 August 2024 | 894 | 894 |
| Charge for the financial year | 537 | 537 |
| | <u> </u> | <u> </u> |
| At 31 July 2025 | 1,431 | 1,431 |
| | <u> </u> | <u> </u> |
| Net book value | | |
| At 31 July 2025 | 1,252 | 1,252 |
| | <u> </u> | <u> </u> |
| At 31 July 2024 | 1,789 | 1,789 |
| | <u> </u> | <u> </u> |

Zephyr Medical Affairs Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

| | | |
|---|----------------------|----------------|
| 6. Debtors | 2025 | 2024 |
| | € | € |
| Trade debtors | 24,000 | 21,096 |
| Director's current account (Note 10) | 228 | - |
| Prepayments | 384 | 504 |
| | <u>24,612</u> | <u>21,600</u> |
| 7. Creditors | 2025 | 2024 |
| Amounts falling due within one year | € | € |
| Taxation | 3,250 | 4,602 |
| Director's current account (Note 10) | - | 1,805 |
| Accruals | 2,583 | 3,383 |
| | <u>5,833</u> | <u>9,790</u> |
| 8. Income Statement | 2025 | 2024 |
| | € | € |
| At 1 August 2024 | 19,438 | 25,423 |
| Profit/(loss) for the financial year | 3,162 | (5,985) |
| At 31 July 2025 | <u>22,600</u> | <u>19,438</u> |
| 9. Capital commitments | | |
| The company had no material capital commitments at the financial year-ended 31 July 2025. | | |
| 10. Director's remuneration and transactions | 2025 | 2024 |
| | € | € |
| Director's remuneration | | |
| Remuneration | 84,774 | 95,900 |
| Pension contributions | 14,400 | 14,400 |
| | <u>99,174</u> | <u>110,300</u> |
| The following amounts are repayable to the director: | 2025 | 2024 |
| | € | € |
| Caroline Kavanagh | - | 1,805 |
| 11. Post-Balance Sheet Events | | |
| There have been no significant events affecting the company since the financial year-end. | | |
| 12. Approval of financial statements | | |
| The financial statements were approved and authorised for issue by the board on 6 January 2026. | | |